Items tagged with Pharma industry
World Health Assembly approves milestone resolution on price transparency (post)
28 May 2019: The World Health Assembly today approved a milestone resolution to support greater public disclosure of prices for medicines and other health products – capping a nail-biting series of negotiations that continued until the very moment the measure came to the floor.
Johnson & Johnson expands efforts to help end TB in India (post)
In advance of the 50th Union World Conference on Lung Health, Johnson & Johnson announced the expansion of its TB program in India. Through a series of new collaborations with several multilateral and non-governmental organizations, as well as the Government of India, the company aims to help support the country's efforts to end TB by 2025, as outlined in its National Strategic Plan for TB Elimination.
TB Alliance announces partnership with Hongqi Pharma to commercialize new therapy for highly drug-resistant forms of TB in China (post)
NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) a license to market the anti-TB medicine pretomanid as part of the three-drug “BPaL” regimen. Hongqi has agreed to commercialize the anti-tuberculosis (TB) medicine in the People’s Republic of China.
Industry urges more government action on antibiotic development (post)
The level of funding for late-stage research and development of new antibiotics and other products to combat antimicrobial resistance (AMR) is insufficient to meet global health needs, and governments need to step up to the plate, according to an industry report released today (January 16).
Publication demonstrates how equitable deals for access to medicines can be signed with pharmaceutical industry (post)
12 Apr 2023 — A new article published today by the Oxford University Press Journal of Intellectual Property Law and Practice shows how fair deals on medical research that ensure equitable access to life-saving medicines can be signed with pharmaceutical companies.
Leaked email: companies intended to campaign against government policy (post with simple image)
A leaked email shows that a plan for a campaign to scuttle the South African government's draft intellectual property policy was about to proceed, despite a denial by the pharmaceutical industry that it had approved the campaign.
TB CAB, CRAG, TAG open letter to AstraZeneca (post with simple image)
Community groups express concern for AstraZeneca's departure from tuberculosis and urge the company to ensure continued investment in the field.
Otsuka: Response to TB CAB, CRAG, TAG open letter (post with simple image)
Otsuka's response to open letter regarding delamanid compassionate use program.
South Africans urge Trade Minister to finalise IP policy before elections and open up access to medicines (post with simple image)
Activists demand rapid completion of intellectual property policy six years in the making; without internationally recognised public health safeguards policy will be health disaster.
Open letter to Otsuka: continued concerns about delamanid's accessibility (post with simple image)
Leading doctors, advocacy groups and medical organizations remain concerned on several fronts regarding access to delamanid.
Page 7 of 9 · Total posts: 0
←First 6 7 8 Last→